FDA Drops Boring Over-the-Counter Drug Fee Rates for 2027
Published Date: 7/30/2026
Notice
Summary
The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Over-the-Counter Monograph Drug User Fee Amendments (herein referred to as "OMUFA II"), authorizes the Food and Drug Administration (FDA, the Agency, or we) to assess and collect user fees from qualifying manufacturers of over-the-counter (OTC) monograph drugs and submitters of OTC monograph order requests (OMORs) for fiscal years 2026 through 2030. This notice publishes the OMUFA fee rates for fiscal year (FY) 2027.
Analyzed Economic Effects
6 provisions identified: 2 benefits, 3 costs, 1 mixed.
Annual Facility Fees for OTC Manufacturers
If you own an over-the-counter (OTC) monograph drug manufacturing facility, the FY 2027 annual facility fee is $47,891 for an OTC monograph drug facility (MDF) and $31,927 for a contract manufacturing organization (CMO) facility (CMO = two-thirds of MDF). These fees are effective October 1, 2026 through September 30, 2027 and are billed in two equal installments due October 1, 2026 and February 1, 2027.
Large Fees for OMOR Submissions
If you submit an OTC monograph order request (OMOR), the FY 2027 fee is $614,608 for a Tier 1 OMOR and $122,921 for a Tier 2 OMOR. OMOR fees are due on the date you submit the OMOR.
Fee Waiver for Safety-Related OMORs
No OMOR fee will be charged if the OMOR seeks certain safety-related changes: (1) changes to drug facts labeling that add or strengthen a contraindication, warning, or precaution; (2) statements about risk associated with misuse or abuse; or (3) dosage/administration instructions intended to increase safe use.
Who Is/Is Not an OMUFA Facility
Facilities that manufacture or process finished-dosage OTC monograph drugs (including relabelers and repackagers) are subject to OMUFA facility fees. Facilities that only manufacture active pharmaceutical ingredients (APIs), produce clinical research supplies, perform testing, or only place outer overpackaging on already final-packaged products are not considered OTC monograph drug facilities for FY 2027.
Payment Methods, Limits, and Collection Consequences
Payments must be in U.S. currency drawn on a U.S. bank via electronic check (ACH), credit card, or wire transfer using FDA's payment portal; credit card payment is available only for balances under $25,000 and ACH is required for larger balances. If an assessed FY 2027 fee is not paid in full, the unpaid balance will be treated as a U.S. Government claim and referred to collection.
Exemption If You Ceased OTC Activity Before Jan 1, 2026
A facility is exempt from FY 2027 facility fees if it ceased OTC monograph drug activities and updated its FDA registration to that effect prior to January 1, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-18612, Medical Devices; Cardiovascular Devices; Classification of the Cardiovascular Machine Learning-Based Notification Software
The Food and Drug Administration (FDA) is classifying the cardiovascular machine learning-based notification software into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the cardiovascular machine learning- based notification software. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
2026-18529, Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device Tracking
The FDA wants your thoughts on how they collect info to track medical devices. This affects companies that make or handle these devices and aims to keep things safe and clear. You’ve got until November 10, 2026, to share your comments—no cost, just your voice!
2026-18551, Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information; Aminobenzoic Acid (PABA) and Trolamine Salicylate
The Food and Drug Administration (FDA or Agency) is announcing the availability on its website of the final administrative order (final order) (OTC000008-1) titled "Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information; Aminobenzoic Acid (PABA) and Trolamine Salicylate." This final order amends "Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use" (Over- the-Counter (OTC) Monograph M020) to remove PABA and trolamine salicylate as sunscreen active ingredients. A sunscreen drug product containing PABA or trolamine salicylate is not generally recognized as safe and effective (GRASE).
Previous / Next Documents
Previous: 2026-15343, Generic Drug User Fee Rates for Fiscal Year 2027
The Federal Food, Drug, and Cosmetic Act (FD&C Act or statute), as amended by the Generic Drug User Fee Amendments of 2022 (GDUFA III), authorizes the Food and Drug Administration (FDA, Agency, or we) to assess and collect fees for abbreviated new drug applications (ANDAs); drug master files (DMFs); generic drug active pharmaceutical ingredient (API) facilities, finished dosage form (FDF) facilities, and contract manufacturing organization (CMO) facilities; and generic drug applicant program user fees. In this document, FDA is announcing fiscal year (FY) 2027 rates for GDUFA III fees.
Next: 2026-15345, Food Safety Modernization Act Voluntary Qualified Importer Program User Fee Rate for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 annual fee rate for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) that is authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA). This fee is effective on August 1, 2026, and will remain in effect through September 30, 2027.